The solution to tackle the hemodialysis site blockage
Chronic kidney disease is a serious and growing health problem affecting millions of patients worldwide.
Today 4.5M patients worldwide suffering of end-stage kidney disease (ESKD) require hemodialysis to replace their kidney function.
Hemodialysis is a long and very restrictive life-saving procedure performed 3 times a week.
To connect the patient to the machine, the best and safest approach is to create a vascular access
Vascular access is the connection between an artery and a vein realized by a surgeon as a arteriovenous fistula (AVF). This is the patient’s lifeline
In the first 6 months after surgery, more than 50% of these AVFs will suffer failure resulting in the blockage of the AVF.
At ArtemiX Biotech, we address this treatment gap.
ArtemiX provides a new generation, patented, long-acting gel administered directly on the AVF after the surgery, helping the AVF to mature (heal) and preventing the blockage of blood flow through the vein.
- Unique Mode of Action
Once in place, the gel releases on the long term the active drug, inhibiting all stages of disease.
- Compliance with human biology
- Very Simple to apply
Right after the arterio-venous surgery, the gel is very easily applied around the vessel by the surgeon without any added surgical procedure.
Artemix Biotech is an early clinical stage spin-off company of the University Hospital of Lausanne and School of Pharmaceutical Sciences of the University of Geneva.
Our products are still under development and not available on the market.